Sustained Response to Temozolomide Rechallenge after Hematological Toxicity in MGMT Methylated Glioblastoma

1. Summary
1.1. Background: Glioblastoma Multiforme (GBM) is known to have a rapidly progressive and fatal clinical course. Methylation of the methylguanine DNA methyltransferase promoter (MGMT) has been associated with a more indolent clinical course and better response to the alkylating agent temozolomide. The standard of care treatment includes radiotherapy with concurrent temozolomide (75mg/m2) followed by adjuvant temozolomide for 6 months (150 mg/m2 at month one, followed by 200mg/m2 given for the remaining 5 months).